The Ethical Case for Decentralized Clinical Trials.

Area of Science:

• Clinical trial design
• Public health
• Medical research

Background:

• The COVID-19 pandemic accelerated interest in innovative clinical trial designs.
• Restrictions on public gatherings led to a rise in remote or decentralized clinical trials (DCTs).

Purpose of the Study:

• To explore the potential of decentralized clinical trials (DCTs) beyond public health emergencies.
• To highlight the advantages and challenges associated with DCTs.

Main Methods:

• This study is a review of the current landscape and potential of DCTs.
• Analysis of benefits such as increased access, reduced burden, and research into rare diseases.
• Consideration of inherent risks and challenges within DCT implementation.

Main Results:

• DCTs offer significant opportunities to improve research accessibility and inclusivity.
• They can extend research benefits to underserved populations and address knowledge gaps in rare conditions.
• Identified challenges are manageable and do not negate the substantial advantages of DCTs.

Conclusions:

• There is a compelling scientific and ethical justification for expanding the use of DCTs.
• DCTs should be considered a valuable tool for clinical research outside of emergency situations.
• Further development and adoption of DCTs are recommended to enhance medical research capabilities.